- $88.40m
- -$4.45m
- $0.86m
U.S. RESEARCH ROUNDUP-Esperion Therapeutics, Office Properties Income Trust, Radius Global Infrastructure
Brief: Rallybio Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Rallybio reports Q4 basic net loss per share of USD 0.46
Brief: Rallybio Announces Proof-Of-Concept Achieved For Rlyb212, A Novel Monoclonal Anti-Hpa-1A Antibody To Prevent Fetal And Neonatal Alloimmune Thrombocytopenia
Brief: EyePoint, Rallybio On Research Collaboration To Evaluate C5, Durasert Tech
Brief: Rallybio Announces Appointment Of Jonathan I. Lieber As Chief Financial Officer
Rallybio gains on promising pre-clinical data from bleeding disorder treatment study
Brief: Rallybio Publishes Data Highlighting Ability Of HPA-1a-Specific Antibodies
U.S. RESEARCH ROUNDUP- Broadcom, Cooper Companies, Interdigital
AbCellera rises on rare disease alliance with Rallybio
Brief: Abcellera & Rallybio To Develop Novel Antibody-Based Therapeutics For Rare Diseases
Brief: Abcellera And Rallybio Announce Strategic Alliance To Discover, Develop And Commercialize Novel Antibody-Based Therapeutics For Rare Diseases
U.S. STOCKS ON THE MOVE-UnitedHealth, Lifestyle, Exxon
U.S. STOCKS ON THE MOVE-LegalZoom, Snail, metal miners
U.S. STOCKS ON THE MOVE-Matterport, Grove Collaborative, Toast
Rallybio slides after stock offering size slashed
Brief: Rallybio Announces Pricing Of $50 Million Public Offering
Brief: Rallybio Announces Proposed Public Offering
Brief: Rallybio Reports Third Quarter Results